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The N termini of the capsid proteins VP1 and VP2 of adeno-associated virus (AAV) play important roles in
subcellular steps of infection and contain motifs that are highly homologous to a phospholipase A2 (PLA2)
domain and nuclear localization signals (NLSs). To more clearly understand how virion components influence
infection, we have generated mutations in these regions and examined their effects on subcellular trafficking,
capsid stability, transduction, and sensitivity to pharmacological enhancement. All mutants tested assembled
into capsids; retained the correct ratio of VP1, VP2, and VP3; packaged DNA similarly to recombinant AAV2
(rAAV2); and displayed similar stability profiles when heat denatured. Confocal microscopy demonstrated that
these mutants trafficked through a perinuclear region in the vicinity of the Golgi apparatus, with a subset of
mutants displaying more-diffuse localization consistent with an NLS-deficient phenotype. When tested for viral
transduction, two mutant classes emerged. Class I (BR1, BR2, and BR2K) displayed partial transduction,
whereas class II (VP3only, 75HD/AN, BR3, and BR3K) were severely defective. Surprisingly, one class II
mutant (BR3K) trafficked identically to rAAV2 and accumulated in the nucleolus, a step recently described
by our laboratory that occurs with wild-type infection. The BR3K mutant, containing an alanine-to-lysine
substitution in the third basic region of VP1, was 10- to 100-fold-less infectious than rAAV2 in transformed cell
lines (such as HEK-293, HeLa, and CV1-T cells), but in contrast, it was indistinguishable from rAAV2 in
several nontransformed cell lines, as well as in tissues (liver, brain, and muscle) in vivo. Complementation
studies with pharmacological adjuvants or adenovirus coinfection suggested that additional positive charges in
NLS regions restrict mobilization in the nucleus and limit transduction in a transformed-cell-specific fashion.
Remarkably, besides displaying cell-type-specific transduction, this is the first description of a capsid mutant
indicating that nuclear entry is not sufficient for AAV-mediated transduction and suggests that additional steps
(i.e., subnuclear mobilization or uncoating) limit successful AAV infection.
Interest in adeno-associated virus (AAV) has been fueled by
its enormous potential as a gene therapy tool, given that it has
never been associated with disease, it can infect a wide variety
of mitotic and postmitotic cells, and therapeutic transgenes can
easily be substituted in place of its coding elements (4). As a
member of the parvovirus family, AAV is one of the smallest
and simplest viruses. It has a diameter of only 25 nm, is non-
enveloped, and cannot replicate on its own. The single-
stranded wild-type viral genome is flanked by two inverted
terminal repeats (TR) that are the only elements necessary for
packaging. Three capsid proteins (VP1, VP2, and VP3) are
encoded in an overlapping reading frame, each beginning with
a different start codon but sharing a common C terminus and
stop codon. Capsids are comprised of 60 proteins, with VP1,
VP2, and VP3 in a ratio of approximately 1:1:10, respectively
(6, 44).
Although AAV has a several properties that make it an
attractive vehicle for gene therapy, transduction is difficult to
achieve in many cell types due to inefficient subcellular traf-
ficking (12, 29, 54). At the cellular level, infection commences
with receptor attachment, which is mediated by glycoproteins
such as heparan sulfate (49, 58, 59). After coreceptor activa-
tion, AAV2 is endocytosed from the cell surface in a clathrin-
and dynamin-dependent process (2, 3, 17). Subsequently, viri-
ons have been reported to traffic through early endosomes (3),
late endosomes, recycling endosomes, and lysosomes (14), and
AAV2 and AAV5 have been visualized in the Golgi apparatus
(2, 47).
As the AAV virion traffics toward the nucleus, amino acid
residues exposed on the capsid surface interact with the sub-
cellular environment and influence its navigation, either di-
rectly or indirectly. Critical components in the capsid that are
necessary for subcellular navigation are harbored near the N
termini of VP1 and VP2 (7, 23, 71). These regions of VP1 and
VP2 are normally inaccessible to antibodies and are thought to
be tucked away in the capsid interior during assembly, but at
some point during infection (prior to endosomal escape), a
conformational change promotes their translocation to the
capsid exterior (5, 36, 56). Two functional elements have been
identified in these N-terminal regions of VP1/2, a phospho-
lipase A2 (PLA2) domain and putative nuclear localization
* Corresponding author. Mailing address: CB #7352, Gene Therapy
Center, University of North Carolina at Chapel Hill, 7113 Thurston
Building, Chapel Hill, NC 27599-7352. Phone: (919) 962-3285. Fax:
(919) 966-0907. E-mail: rjs@med.unc.edu.
† Supplemental material for this article may be found at http://jvi
.asm.org/.
 Published ahead of print on 23 June 2010.
8888
signals (NLS). These elements are conserved in almost all
parvoviruses (7), with a sequence of about 70 amino acids in
VP1 being highly homologous to the catalytic domain of se-
cretory PLA2. Mutating the histidine and aspartic acid catalytic
dyad of PLA2 to alanine and asparagine (
75HD/AN) does not
affect cell surface attachment or endocytosis of the virus but
strongly inhibits PLA2 activity and renders the virus severely
defective, which has been shown to result in a decrease in
transduction of roughly 3 orders of magnitude (23, 56, 71).
Phospholipase action is surmised to mediate the membrane
disruption of a vesicular compartment, which would permit the
escape of the virion into the cytosol, although this has yet to be
directly demonstrated for AAV.
The vast majority of genomes remain outside the nuclear
membrane (12, 29), but ultimately, the transgene must be de-
livered to the nucleus, transition from a single-stranded ge-
nome to a double-stranded intermediate, and convert to a
stable double-stranded form before transduction is considered
complete (62). We have previously shown that capsids are
capable of entering the nucleus intact (33), but the precise
location for uncoating is still debated. The transport of mac-
romolecules such as parvoviruses across the nuclear membrane
is an ATP-dependent process and is mediated by soluble cy-
tosolic factors, like Ran-1, that interact with specific NLSs on
target proteins (25, 46). NLSs have been identified on VP1s
from various parvoviruses that are integral to nuclear targeting
(40, 41, 60). The first 10 residues of VP1 in canine parvovirus
has been identified as an NLS (60), and minute virus of mice is
known to have a bipartite NLS (41), yet these residues are not
conserved in AAV. Several patches of hydrophilic, basic re-
gions (also considered basic clusters) have been identified in
AAV2 capsid proteins (Fig. 1A), termed BR1 (only in VP1),
FIG. 1. Mutations in VP1/2 N termini affect transduction of rAAV. (A) The AAV genome contains genes that code for Rep proteins involved
in replication and Cap proteins that comprise the capsid. Specific Cap proteins harbor a phospholipase domain (PLA2) (HD) and basic regions
(BR) () that are putative nuclear localization signals. (B) Capsid mutants used in this study are listed by sequence, and amino acid changes are
shown in red letters. (C) Western blot (WB) analysis of purified virus (5  109 vg) blotted with antibody B1, which detects VP1, VP2, and VP3.
(D and E) Luciferase assay of transduction in HEK-293 cells (D) and HeLa cells (E). Cells were inoculated with rAAV2 or mutants that package
TR-CMV-Luc (10,000 vg/cell), and luciferase activity was quantified 24 h later. Error bars represent standard deviations from three independent
samples.
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BR2, and BR3 (in VP1 and VP2) (27, 56). Mutating these
regions results in a graduated loss of infectivity compared
to recombinant AAV2 (rAAV2): roughly 1 log order for BR1
(120QAKKR/QANNR), 2 log orders for BR2 (140PGKKR/
PGNNR), and 3 log orders for BR3 (168PARKR/PANNR) (27,
67). While it is known that these mutations negatively impact
the infectivity of AAV2, their influence on subcellular traffick-
ing in the context of the virion has not been studied in depth.
Evidence from one of the most robust and well-studied
NLSs, found in the large T antigen of simian virus 40 (SV40),
suggests that the number of positive charges in an NLS corre-
lates to the strength of its function (34, 35). The putative NLS
regions in AAV are not as extensive as those in other viruses,
so we reasoned that this might at least partially explain why the
nuclear targeting of AAV is inefficient. Thus, we attempted to
see if the BR2 and BR3 regions could be manipulated to (i)
tolerate an additional positive charge and (ii) mediate en-
hanced nuclear targeting and transduction. Thus, for these
studies we have engineered a collection of mutant capsids
containing amino acid substitutions or deletions in the N ter-
mini of VP1 and VP2 and have explored how these mutations
influence subcellular trafficking and transduction. Here we re-
port that these mutants display subtle differences in their traf-
ficking profiles: in contrast to rAAV2, mutants that lack a
PLA2 domain or positive charge in NLS regions cannot be
detected in the nucleus. The BR1 mutant targets mainly to
the Golgi apparatus, whereas BR2 and BR3 display a
slightly more diffuse localization, distal from the nucleus. We
have generated one mutant, containing a lysine-to-alanine sub-
stitution in BR3 (168PARKR/PKRKR [BR3K]), that was 10-
to 100-fold-less infectious than rAAV2 in certain cell types but
was able to transduce as well as rAAV2 in mouse liver, muscle,
and rat brain in vivo and other cultured cells in vitro. Surpris-
ingly, despite BR3K being defective in transducing HeLa
cells, the capsid was still able to enter the nucleus with the
transgene. In addition to suggesting that nuclear entry is not
sufficient for transduction, our results imply that additional
positive charges in NLS regions may restrict mobilization in
the nucleus and limit transduction in a cell-specific manner
that appears to be linked to the transformation state of the cell.
The availability of these mutant capsids and permissive and
nonpermissive cell lines should aid in dissecting specific steps
in subcellular trafficking required for successful AAV infec-
tion, which might eventually advance the design of AAV-based
vectors.
MATERIALS AND METHODS
Cell culture. HeLa, HEK-293, C2C12, and HepG2 cells were maintained at
37°C and 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) that was
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml
penicillin, and 100 g/ml streptomycin. CV1 and CV1-T cells (also known as Cos-7
cells) were maintained under the same conditions but with Eagle’s minimum
essential medium (MEM) supplemented with 10% FBS and 1% penicillin-strep-
tomycin.
PCR site-directed mutagenesis. Capsid mutations were generated in the pXR2
backbone as previously described (27), with minor modifications. PCR was per-
formed with the Expand Long Template PCR kit (Roche) according to cycle
guidelines listed in the manual for QuikChange site-directed mutagenesis (Strat-
agene). PCR products were digested with DpnI and transformed into DH10B
bacteria, which were selected on ampicillin-containing agar plates. Single colo-
nies were picked and grown in liquid cultures overnight, and plasmids were
isolated by column purification (Qiagen). Mutations were verified by sequencing
of the plasmids utilizing the University of North Carolina—Chapel Hill (UNC-
CH) Automated DNA Sequencing Facility with a 3100 Genetic Analyzer (Ap-
plied Biosystems).
Virus production. Virus was produced in HEK-293 cells as previously de-
scribed (69). Briefly, polyethylenimine (linear molecular weight, 25,000) was
used to for the triple transfection of the pXR2 cap and rep plasmid, the pXX6-80
helper plasmid, and a TR-Luciferase or TR-eGFP reporter plasmid containing
either firefly luciferase (Luc) or enhanced green fluorescent protein (GFP)
transgenes flanked by inverted terminal repeats. Cells were harvested at between
48 and 72 h posttransfection, and virus was purified by cesium chloride gradient
density centrifugation. After identifying peak fractions by dot blot hybridization,
virus was dialyzed into 1 phosphate-buffered saline (PBS) containing 5% sor-
bitol. Titers were calculated by quantitative PCR (qPCR) according to estab-
lished procedures (33) by using a LightCycler 480 instrument with Sybr green
(Roche) and primers designed against the Luc transgene, 5 AAA AGC ACT
CTG ATT GAC AAA TAC 3 (forward) and 5 CCT TCG CTT CAA AAA
ATG GAA C 3 (reverse), or the GFP transgene, 5 AGC AGC ACG ACT TCT
TCA AGT CC 3 (forward) and 5 TGT AGT TGT ACT CCA GCT TGT GCC
3 (reverse). Conditions used for the reaction were as follows: 1 cycle at 95°C for
10 min; 45 cycles at 95°C for 10 s, 62°C for 10 s, and 72°C for 10 s; and 1 cycle
at 95°C for 30 s, 65°C for 1 min, and 99°C for acquisition. Adenovirus (Ad)
mutant stocks were generously provided by Pat Hearing or generated in the
laboratory, produced and purified as previously described (20, 30).
Confocal immunofluorescence microscopy. Similar to what we have previously
described (26), HeLa cells (5  104 cells/well) were plated onto poly-L-lysine-
coated 12-mm glass coverslips (thickness, 1.5) between 4 and 16 h before inoc-
ulation. Recombinant virions were added to cell media at the indicated particle
numbers. No virus was added to control wells. Where indicated, hydroxyurea
(HU; Sigma) was added at 10 mM for 12 h and washed off extensively prior to
virus administration. A proteasome inhibitor (MG132; Calbiochem) was present
for the duration of virus inoculation at 2 M, when used. At the indicated time
points, cells were washed three times with PBS and then fixed with 2% parafor-
maldehyde for 15 min at room temperature. The cells were then permeabilized
with 0.1% Triton X-100 in PBS for 5 min at room temperature. Following four
washes with PBS, the permeabilized cells were blocked with immunofluorescence
buffer (IFB) (20 mM Tris [pH 7.5], 137 mM NaCl, 3 mM KCl, 1.5 mM MgCl2,
5 mg/ml bovine serum albumin, 0.05% Tween) for 30 min at room temperature.
The cells were incubated with primary antibody to detect intact capsids (mono-
clonal antibody [MAb] A20 [1:10], nucleolin (NCL) [Ab22758, 1:1,000; Abcam],
lamin B1 [Ab16048, 1:750; Abcam], giantin [Ab24586, 1:1,000; Abcam], and
polyclonal anti-VP1 (VP1)-147/148 [1:1,000]) diluted in IFB for 1 h at 37°C or
overnight at 4°C. The cells were then incubated in secondary antibody diluted
1:5,000 in IFB (anti-mouse Alexa Fluor 488 or anti-rabbit Alexa Fluor 568;
Molecular Probes) for 1 h at 37°C. After six washes in PBS, coverslips were
mounted cell side down onto glass slides with mounting medium (Prolong An-
tifade gold with DAPI [4,6-diamidino-2-phenylindole]; Molecular Probes). Im-
ages were captured on a Leica SP2 AOBS upright laser scanning confocal
microscope and processed by using Adobe Photoshop.
Three-dimensional (3D) rendering of infection. Confocal z-stack sections of
HeLa cells fixed 16 h after infection with either rAAV2 or mutant virions
(10,000 vector genomes [vg]/cell) were processed and rendered in three
dimensions by using Volocity software (Improvision) in the Michael Hooker
Microscopy Facility.
Cell fractionation and nucleolar isolation. Nucleoli were isolated from cell
fractionations as previously described (43), with minor modifications allowing for
viral infection (33). Briefly, five 15-cm plates of HeLa cells at 90% confluence
were used for each preparation. rAAV2 or mutant virions were incubated with
cells for 16 h at 37°C (2,000 vg/cell). Cells were washed three times with ice-cold
PBS, trypsinized, and harvested by centrifugation at 218  g for 5 min. The cell
pellet was resuspended in hypotonic buffer and homogenized on ice using a tight
pestle to the point where 90% of cells were burst (approximately 15 strokes)
and leaving nuclei intact. The homogenate was spun at 218  g for 5 min to
separate the crude nuclear pellet from the postnuclear supernatant (5 ml).
Nuclei were further purified from cytoplasmic contaminants by spinning through
a 0.35 M sucrose cushion to give a nuclear-associated pellet. Nuclei were lysed by
limited sonication on ice, and the nuclear suspension in 0.35 M sucrose was
layered over a 0.88 M sucrose cushion to separate nucleoli (200 l) from bulk
nuclear fractions (5 ml). Nucleoli were further purified by another spin through
sucrose, and their integrity and purity were verified by phase-contrast microscopy
and Western blotting.
Transduction assays. At least 4 h prior to infection or drug treatment, cells
were plated in 24-well plates at densities to approximate 70% confluence (2 
105 cells/well for HEK-293 cells and 7  104 cells/well for other lines). For drug
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studies, cells were handled as stated above. Cells were infected with purified
rAAV2 at the designated number of vector genomes per cell and typically
harvested after 24 h unless otherwise noted. Luciferase activity was measured in
accordance with the manufacturer’s instructions (Promega) using a Wallac1420
Victor2 automated plate reader. Error bars represent standard deviations from
samples scored in triplicate. Graphs are representative of data sets from at least
three independent assays.
Western blotting. As reported previously (33), samples from purified virus or
cell fractionations were loaded onto NuPage 10% Bis-Tris gels and typically run
for 3 h at 150 V in 1 NuPage MOPS (morpholinepropanesulfonic acid) buffer.
Electrophoresis was performed with the XCell SureLock minicell (Invitrogen).
Proteins were transferred onto a Hybond ECL membrane utilizing the XCell II
blot module (Invitrogen) according to the manufacturer’s protocol. Membranes
were blocked in 5% nonfat dry milk (NFDM) dissolved in 1 PBS–Tween
(0.1%) (PBST). For the detection of capsid proteins, primary antibody (MAb
B1) was diluted 1:20 with 2.5% NFDM in PBST and incubated for 1 h at room
temperature or overnight at 4°C. After washing with PBST, blots were incubated
for 1 h at room temperature with anti-mouse horseradish peroxidase (HRP)
secondary antibody diluted 1:5,000 in 2.5% NFDM with PBST. Following mul-
tiple washes with PBST, SuperSignal West Femto maximum-sensitivity substrate
(Pierce) was added to each membrane according to the manufacturer’s protocol
for development. Each membrane was then exposed to Hyperfilm ECL (Amer-
sham).
Immunoblot after limited heat treatment. To examine capsid stability and VP1
exposure, purified virions (1  109 vg/sample) were heat treated over a range of
temperatures between 37°C and 75°C for 10 min in PBS, and samples were then
split for detection with separate antibodies (2.5  109 vg/well) blotted onto a
nitrocellulose membrane through a dot blotting apparatus. The membrane was
processed as described above for Western blotting by using antibodies to detect
intact capsids (monoclonal A20 [1:10]), exposed VP1 N termini (monoclonal A1
[1:20] and polyclonal VP1-147/148 [1:1,000]), disassembled subunits (monoclo-
nal B1 [1:2,000]), and appropriate secondary antibodies conjugated to HRP.
Data are from representative blots from experiments performed in triplicate.
EM. As previously described (15), purified and dialyzed full rAAV2 or
BR3K virus particles (109 vg) were pipetted onto a glow-discharged copper
grid. The grid was washed twice with water and then stained with 2% uranyl
acetate. Electron microscopy (EM) images were taken with a LEO EM 910
transmission electron microscope at several magnifications at the University of
North Carolina Microscopy Services Laboratories.
FISH to detect viral genomes. HeLa cells were plated onto chamber slides
(Nunc) coated with poly-L-lysine (25  103 cells/well) 24 h prior to infection.
rAAV2 or BR3K virions were administered (10,000 vg/cell) for 16 h before the
cells were washed four times with PBS and fixed with 4% paraformaldehyde for
15 min at room temperature. Cells were then treated with protease K (0.5 g/ml)
for 5 min, washed with PBS, and fixed again in paraformaldehyde. The samples
were then treated with triethanolamine-HCl with acetic anhydride for 10 min at
room temperature, washed with PBS, and prehybridized for 2 h at 65°C in
prewarmed hybridization buffer. A digoxigenin-labeled sense-strand RNA probe
complementary to the vector genome was synthesized by using T7 polymerase
and spanned a 1-kb fragment of the firefly luciferase transgene. The probe was
added to samples in hybridization buffer overnight at 65°C, and after washing
steps, the digoxigenin label was detected by using the Roche Fast Red kit for
fluorescent in situ hybridization (FISH), and the slides were then covered with
coverslips and mounted with DAPI to detect cell nuclei.
Vector administration and animal studies. Housing and handling of BALB/c
mice and Sprague-Dawley (Harlan) rats used in the current study were carried
out in compliance with National Institutes of Health guidelines and approved by
the IACUC at the University of North Carolina—Chapel Hill. Recombinant
AAV2 vectors or mutants packaging Luc transgenes were administered through
the intramuscular (1  1010 vg into the hind limb; gastrocnemius muscle) in a
volume of 50 l PBS or through the intravenous route (tail vein) in a volume of
200 l PBS. Bioluminescence of Luc expression was visualized by using a Xeno-
gen IVIS100 imaging system (Caliper Lifesciences) after intraperitoneal injec-
tion of luciferin substrate (120 mg/kg of body weight; Nanolight). Image acqui-
sition and analysis were carried out by using Living Image software. Data are
representative images from only one mouse, but results were reproduced con-
sistently using three or four mice for each vector group, and average values are
included in the supplemental material.
For vector infusions into rat brain, animals were anesthetized with isoflurane
and placed into a stereotaxic frame. Using a 32-gauge stainless steel injector and
a Fisher Scientific infusion pump, rats (n 	 2) received 3 l per hemisphere
(total of 3.8  108 vg) AAV2-CBA-GFP (left hemisphere) and BR3K-CBA-
GFP (right hemisphere) into the striatum (bregma, 1.0 mm; lateral, 
3.0 mm;
vertical, 5.0 mm [based on a brain atlas {48}]) over 15 min. The injector was
left in place for 3 min after infusion to allow diffusion from the injector. Two
weeks after intracerebral injection, animals received an overdose of pentobarbi-
tal (100 mg/kg intraperitoneally) and were perfused transcardially with ice-cold
100 mM sodium PBS (pH 7.4), followed by 4% paraformaldehyde in phosphate
buffer (PB) (pH 7.4). After brains were postfixed for 48 h at 4°C in paraformal-
dehyde-PB, 40-m coronal sections were cut using a vibrating-blade microtome
and subjected to immunohistochemical processing for GFP. Colorimetric GFP
detection was performed by incubating free-floating sections with a rabbit poly-
clonal antibody to GFP (1:1,000; Millipore). Briefly, sections were blocked in
10% normal goat serum and 0.1% Triton X-100 in PBS for 1 h. The sections were
then incubated with anti-GFP primary antibody (prepared in 3% normal serum–
0.2% Triton X-100) for 48 to 72 h at 4°C with gentle agitation. Immunoperoxi-
dase staining was then performed by using the anti-rabbit Vectastain Elite ABC
kit (Vector Laboratories) according to the manufacturer’s instructions, with
3,3-diaminobenzidine (DAB) substrate and nickel-cobalt intensification of the
reaction product. Brain sections were mounted onto slides, covered with a cov-
erslip, and digitized by using a Scan-Scope slide scanner (Aperio Technologies).
Virtual slides were viewed and images were captured by using the ImageScope
software package (v. 10.0; Aperio Technologies).
Statistical analyses. When luciferase activity after the transduction of rAAV2
and the BR3K mutant was evaluated (see Fig. 7A and B), a two-tailed Stu-
dent’s t test was used to compare means. A P value of 0.01 was considered
significant and is marked in the figures with an asterisk. All data were analyzed
by using Excel software (Microsoft).
RESULTS
Mutations in VP1/2 N termini affect transduction of rAAV.
Through PCR mutagenesis we have generated capsid mutants
that lack VP1 and VP2 (VP3only), lack PLA2 activity (
75HD/
AN) (23), lack positive charges in VP1 and VP2 (BR1, BR2,
and BR3), or have additional positive charges in the latter
basic regions (BR2K and BR3K) (Fig. 1B). Each of these
mutants was found to assemble into capsids and produce titers
of magnitudes similar to that of rAAV2 (data not shown).
Western blot analysis of 5  109 vector genomes shows that
VP3only capsids carry no detectable levels of VP1 or VP2,
whereas the remaining mutants contain appropriate stoichio-
metric ratios of VP1, VP2, and VP3 at roughly 1:1:10, respec-
tively (Fig. 1C). After assessing several different preparations
of virus, no significant variation in VP1 or VP2 incorporation
was found to be different from rAAV2 in any of the mutants,
as depicted by the representative blot shown in Fig. 1C. These
results corroborate previous reports that VP1 and VP2 do not
play an obvious role in packaging (63). However, mutations in
these capsid proteins have striking effects on transduction, with
similar profiles for HEK-293 and HeLa cells (Fig. 1D and E).
Previously, we identified through prediction mapping software
that there are four potential NLS regions in AAV2 (27). The
first three basic regions, BR1, BR2, and BR3, were found to be
important for transduction, but the fourth was required for
capsid assembly. Mutation of BR2 and BR3 to include neutral
amino acids was shown to have the most negative impact on
transduction, similar to what Sonntag et al. observed previ-
ously after mutating these basic regions to negative amino
acids (56). Since these regions appeared to be most important
for transduction, we wanted to assess whether these regions
would tolerate an additional positive charge in an attempt to
increase the strength of their NLS activities, similar to what
was demonstrated previously for the large T antigen of SV40
(34, 35, 64). The VP3only, 75HD/AN, BR3, and BR3K
mutants seemed to be the most defective of the group, as it was
difficult to distinguish any difference from background light
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units (log relative light units [RLUs], 2). Thus, these mutants
could be divided into two classes: class I mutants (BR1,
BR2, and BR2K), which were partially deficient, and class
II mutants (VP3only, 75HD/AN, BR3, and BR3K), which
were markedly deficient. It is noteworthy that these results
were consistent when using different reporters (Luc or GFP),
different promoters (cytomegalovirus [CMV] or CBA), and a
wide range of particle numbers (from 100 to 20,000 vg/cell)
(data not shown). In each case the BR3K mutant was se-
verely compromised in HEK-293 and HeLa cells, transducing
at least an order of magnitude less efficiently than rAAV2.
Subcellular localization of capsid mutants. Previous studies
demonstrated that a significant percentage of AAV capsids
colocalize with the Golgi apparatus during subcellular traffick-
ing (2, 47); therefore, we used this area as a point of reference
for analyzing whether mutants traffic differently than rAAV2 in
HeLa cells, in an attempt to link capsid localization with a
corresponding defect in transduction. HeLa cells were inocu-
lated with rAAV2 or mutant virions for 16 h and prepped
samples for immunofluorescence microscopy using antibodies
to detect intact capsids (A20) or a Golgi marker (giantin). A
variety of localization patterns was observed for rAAV2 and
mutant capsids; however, cells that were most representative of
the population were selected for analysis. Using z-stacked con-
focal slices of inoculated cell samples, we were able to generate
three-dimensional renderings of infection with volume imaging
software. We found that all mutants were able to bind and
efficiently internalize into HeLa cells to the same extent. These
vectors displayed either partial or significant colocalization
with the Golgi apparatus (Fig. 2). We observed pronounced
Golgi localization with the BR1 mutant, more so than with
any other mutant, although the significance of this is not yet
clear (see Discussion). The BR2 and BR3 capsid mutants
appear to have diffuse localization throughout the cell in ad-
dition to localizing to the Golgi. This finding supports the idea
that BR2 and BR3 are important for nuclear localization, but
it is unknown if these mutant capsids remain in endosomal
compartments at distal regions or have escaped into the cyto-
plasm. Considering the observation that a population of even
the most defective class II mutants traffic to the Golgi appa-
ratus during infection, namely, VP3only and 75HD/AN parti-
cles, one could speculate that accumulation in Golgi-associated
vesicles is a default sorting pathway taken by the virus, which
does not require PLA2 or NLS function.
Exposure of VP1 N termini. Many viruses undergo a matura-
tion process during entry into cells that is necessary for infection
to progress. Parvoviruses follow this paradigm, with late subcel-
lular events of infection hinging on the exposure of VP1/2 N
termini (36, 56). To establish whether VP1/2 N termini were
appropriately exposed in mutant capsids during infection, we em-
ployed antibodies that have been generated to specifically detect
either intact capsids (A20), VP1 N termini (A1/anti-VP1) with the
exposed phospholipase domain, or disassembled subunits (B1)
(Fig. 3A) (66). The extrusion of VP1/2 N termini can be induced
in vitro by limited heat treatment or urea. Kronenberg et al.
reported previously that empty capsids fail to expose VP1 at
temperatures that expose VP1 in rAAV2 (37). Here, we have also
demonstrated this result by treating purified rAAV2 and empty
capsids with a range of temperatures and subsequently immuno-
blotting samples onto nitrocellulose with the above-mentioned
antibodies (Fig. 3B). In contrast to empty capsids, virions with
mutations in VP1 N termini are able to expose VP1 similarly to
rAAV2 after limited heat treatment. Epitopes on VP1 become
exposed after incubation at 60°C (reactive to anti-VP1), with
capsids remaining intact, as indicated by A20 reactivity and the
lack of B1 reactivity (Fig. 3C).
We also visualized VP1 exposure during infection in HeLa
cells using indirect immunofluorescence confocal microscopy
FIG. 2. Subcellular localization of capsid mutants. Volume imaging software was used to process z-stacked confocal images of HeLa cells
infected with capsid mutants (10,000 vg/cell) for 16 h. Capsids (green) are shown in relation to the Golgi marker giantin (red) and nuclei (blue).
All mutants, along with rAAV2, display some level of colocalization with the Golgi apparatus, with the BR1 mutant being the most intense. The
BR2 and BR3 capsid mutants appear to have diffuse localization throughout the cell in addition to localizing to the Golgi apparatus compared
to the localization of rAAV2 and other mutants.
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(Fig. 3D). The signal for exposed VP1 (red) (anti-VP1) over-
laps with the signal for capsids (green) (A20) in a perinuclear
region that corresponds mainly to the Golgi apparatus and
associated COPI vesicles (data not shown). Supporting our
findings from immunoblotting capsids after limited heat treat-
ment, we demonstrate here that we cannot detect a significant
exposure of VP1 N termini on empty capsids, which provides
an explanation of why empty capsids do not enter the nucleus
and fail to accumulate in the nucleolus (33). As a negative
control, VP3only particles, which lack VP1, show no significant
signal from VP1. Additionally, we found that other mutants
(75HD/AN and BR3) are still capable of exposing VP1 during
entry. Similar results were obtained with antibody A69, which
detects the N termini of both VP1 and VP2 (data not shown).
Thus, we conclude that these capsid mutants are deficient after
the conformational change, at steps in infection such as endo-
somal escape or nuclear targeting.
Effect of proteasome inhibition on nucleolar accumulation
and transduction of capsid mutants. Since all mutant capsids
except VP3only were able to expose VP1/2 N termini, we next
tested whether any capsids could be detected in the nucleus
and if their deficient transduction profiles could be rescued
with a pharmacological adjuvant. Proteasome inhibitors are
known to be one of the most potent agents for enhancing the
transduction of AAV in certain cell types and have been shown
to increase the nuclear accumulation of virions (13). The spe-
cific mechanisms by which proteasome inhibitors act to im-
prove transduction remain unclear, but several hypotheses
FIG. 3. Exposure of VP1 N termini. (A) Antibodies that specifically detect either intact capsids (A20), VP1 N termini (A1/VP1), or
disassembled subunits (B1) permit analysis of conformational changes in vitro in response to limited heat treatment or in cells during infection (i.e.,
exposure of the phospholipase and NLS motifs). (B) Immunoblot showing exposure of VP1 N termini. rAAV2 virions or empty capsids were
exposed to limited heat treatment after limited heat treatment at designated temperatures for 10 min, applied onto nitrocellulose membranes,
incubated with the antibodies shown, and developed after processing for chemiluminescence. Empty capsids are more resistant to exposing VP1.
(C) Immunoblot comparing VP1 exposure among capsid mutants (1  109 vg/well). Capsids disassemble prior to 75°C, as indicated by the loss of
A20 reactivity and gain of B1 reactivity. An intermediate conformational change exists after heating capsids to 60°C, where VP1 epitopes are
detected but capsids remain intact. (D) Immunofluorescence microscopy demonstrating VP1 exposure during infection. Capsids (green) display
VP1 exposure (red) in a perinuclear region. Empty capsids, which are deficient in VP1 exposure, and VP3only particles, which lack VP1, show no
significant signal from VP1 (amino acids [aa] 2 to 16). The two mutants that are least infectious, 75HD/AN and BR3, have not lost the ability
to expose VP1 during infection, implicating dysfunction in later steps during infection as the cause of the lost transduction.
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have been put forth: they increase the nuclear delivery of AAV
(18), increase the ubiquitination of capsids (70), inhibit the
clearance of viral capsids, inhibit the clearance of viral ge-
nomes (16), and potentiate the accumulation of virions in the
nucleolus (33). We explored the effects of the proteasome
inhibitor MG132 on capsid localization using indirect immu-
nofluorescence microscopy (Fig. 4A). In the presence of
MG132, rAAV2, BR2K, and BR3K capsids (green) were
found to accumulate in the nucleus. We found that the
VP3only, 75HD/AN, BR1, BR2, and BR3 mutants were
restricted mostly to extranuclear regions and were not ob-
served within the nuclear membrane (dotted line traced from
DAPI staining). We corroborated these findings by subcellular
fractionation and detected the most abundant capsid protein,
VP3, from rAAV2, BR2K, and BR3K capsids in nucleolar
isolations (Fig. 4B). To a much lesser extent, capsid proteins
from the BR1 and BR2 mutants were detectable at faint
levels in these fractions.
Interestingly, the pattern for transduction enhancement with
proteasome inhibitors did not match the observed effect on
capsid localization. Only rAAV2, BR1, and BR2K trans-
duction profiles were augmented by MG132 treatment, as de-
FIG. 4. Effect of proteasome inhibition on nucleolar accumulation and transduction of capsid mutants. MG132 (2 M) was administered to
HeLa cells simultaneously with virions (10,000 vg/cell), and after 16 h, samples were prepped for immunofluorescence microscopy. rAAV2,
BR2K, and BR3K capsids (green) are found to accumulate in the nucleus (white arrows), and VP3only, 75HD/AN, BR1, BR2, and BR3
capsids are restricted mostly to extranuclear regions. (B) Subcellular fractionation of nucleoli after infection. HeLa cells were infected with mutant
virions (1,000 vg/cell) for 16 h and subjected to subcellular fractionation. Capsid proteins from rAAV2 and the BR2K and BR3K mutants were
detected in nucleolar fractions by Western blotting. (C) Luciferase assay of transduction in the presence of proteasome inhibitor. HEK-293 cells
were infected (10,000 vg/cell) for 24 h in the presence of MG132 (2 M) and then scored for transduction efficiency. Error bars represent standard
deviations from three independent samples.
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termined by a luciferase assay (Fig. 4C). The most perplexing
discrepancy was seen with the BR3K mutant, a mutant that
was found to accumulate in nucleoli in response to MG132, as
shown by indirect immunofluorescence and subcellular frac-
tionation. Surprisingly, the transduction of this mutant was not
enhanced in the presence of MG132. This finding raised sev-
eral questions. Do BR3K capsids release their genome pre-
maturely, prior to nuclear entry, or are BR3K capsids unable
to release their genome once within the nucleus? Furthermore,
will the transduction of BR3K be rescued under certain con-
ditions? We have attempted to address these questions with
the remainder of the study.
Stability of BR3K capsids compared to that of rAAV. It is
possible that BR3K capsids are either less or more structur-
ally stable than rAAV2, which could promote an early loss of
genomes before capsids have entered the nucleus or, con-
versely, prevent genome ejection/uncoating after the capsid
has entered the nucleus. Thus, we set out to determine if
BR3K capsids were physically different from rAAV2 in terms
of their ultrastructural appearance as judged by electron mi-
croscopy, capsid sensitivity to limited heat treatment, and ge-
nome sensitivity to DNase. No obvious structural differences
were apparent between rAAV2 and BR3K capsids when
examined by electron microscopy (Fig. 5A). We also submitted
these capsids to a refined heat gradient using eight tempera-
tures between 37°C and 75°C. In this assay rAAV2 and
BR3K capsids were comparable with respect to thermosta-
bility, as VP1 N termini become exposed after 57°C, and dis-
assembled subunits could be detected prominently for both
capsids after samples reached 65°C (Fig. 5B). A subtle differ-
ence in the B1 signal was seen at lower temperatures, with
BR3K samples being slightly more reactive, but this could
not be reliably reproduced (data not shown). Next, we tested if
BR3K genomes were more sensitive to DNase treatment,
which would indicate that genomes in BR3K capsids might
be less protected during infection. After heat treatment, viri-
ons were treated with DNase for 30 min, the DNase was then
inactivated with EDTA, and the remaining genomes were
quantified by qPCR. For both rAAV2 and the BR3K mutant,
genomes first became susceptible to DNase once temperatures
that extruded VP1 N termini were reached (Fig. 5C), similar to
what was observed previously for other parvoviruses (10, 11,
42, 50). Again, no difference in sensitivity to DNase between
rAAV2 and BR3K virions was reliably reproduced. From
these assays, we conclude that the BR3K mutant has no
observable effects on capsid ultrastructure, thermostability, or
DNase sensitivity.
Fluorescent in situ hybridization depicting that DNA from
the BR3K mutant is delivered to the nucleus during infec-
tion. Because the above-described in vitro assays of stability did
not uncover any differences between rAAV2 and BR3K cap-
sids, we hypothesized that an uncoating mutant phenotype may
be more striking in the context of infection. Therefore, to
determine if BR3K capsids jettison their genomes into the
cytoplasm or, in contrast, carry their genomes into the nucleus
where the capsid may fail to uncoat, we used fluorescent in situ
hybridization (FISH) to visualize the localization of viral ge-
nomes. HeLa cells were inoculated with rAAV2 or the
BR3K mutant for 16 h and prepped for FISH by using an
RNA probe that detects single-stranded TR-GFP genomes of
minus-strand polarity, to avoid the detection of transcribed
mRNA. Similar to what was found with capsid localization, the
majority of viral genomes (red) accumulated in a perinuclear
region (Fig. 6ii and iii). When the proteasome inhibitor
MG132 was administered concurrently with virus, we found
that the genomes were delivered to the nucleus and accumu-
lated in the nucleolus (Fig. 6v and vi). When uninfected cells
were processed for FISH, no signal could be detected, indicat-
ing that the probe is specific to the viral genome (Fig. 6i and
iv). Since the BR3K mutant fails to transduce HeLa cells, yet
BR3K capsids and genomes are found to enter the nucleus,
this strongly suggests that the mutant is impeded from transi-
tioning to a nuclear location in this cell type where uncoating
can occur. Perhaps the most salient conclusion from this find-
ing is that the nuclear entry of AAV is not sufficient for trans-
duction.
FIG. 5. Stability of BR3K capsids compared to rAAV. (A) Purified virus preparations were subjected to uranyl-acetate negative staining and
applied onto discharged copper grids for electron microscopy. The scale bar represents 50 nm. (B) Immunoblotting of antibody reactivity after
limited heat treatment (10 min at designated temperatures) indicates that rAAV2 and BR3K capsids have similar macromolecular stabilities.
Capsids are no longer intact at 75°C (A20), VP1 N termini become exposed after 57°C, and disassembled subunits can be detected prominently
for both capsids at 65°C. (C) After heat treatment, virions were treated with DNase and submitted to qPCR to compare genome protections.
rAAV2 and the BR3K mutant have similar patterns of DNase sensitivity after heat treatment. The line graph is representative of data from one
of three experiments.
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BR3K capsids cannot be efficiently mobilized to the nu-
cleoplasm. Previous work identified that at least two separate
trafficking pathways in the nucleus can be taken by rAAV2
capsids: a pathway that results in nucleolar accumulation and a
second pathway that mobilizes capsids to the nucleoplasm (33).
In a prior work we have demonstrated that hydroxyurea (HU)
disrupts the nucleolus, which is consistent with data from other
reports (51). Treatment with HU results in a reorganization of
nucleolar proteins, and concomitantly, virus capsids localize to
the nucleoplasm (33). As we have shown that the BR3K
mutant can accumulate in the nucleolus in the presence of
proteasome inhibitors, we next asked if this mutant could be
mobilized to the nucleoplasm in response to HU treatment. To
build on our earlier findings, we inoculated HeLa cells with
rAAV2 or the BR3K mutant for 16 h after pretreatment with
HU (10 mM for 12 h) and prepped samples for confocal
immunofluorescence. After rendering z-stacked sections into
3D projections (described in Materials and Methods), a movie
was generated to visualize capsids that had been internalized
into the cell (Fig. 7, and see Movie S1 in the supplemental
material). The channels for the nucleus (blue) and nucleoli
(red) were digitally subtracted (Fig. 7ii to iv and Movie S1) to
reveal that rAAV2 and BR3K virions (green) accumulate in
HeLa cell nucleoli when infection is performed in the presence
of MG132 (Fig. 7 and Movie S1). However, only rAAV2 cap-
sids were significantly affected by HU and mobilized to the
nucleoplasm (Fig. 7 and Movie S1). BR3K capsids were not
efficiently mobilized to the nucleoplasm following HU treat-
ment, which further implicates the nucleoplasm, and not the
nucleolus, as a site for uncoating.
Adenovirus potentiates transgene expression from the
BR3K mutant. Since the possibility remains that a small
percentage of BR3K virions are able to infect HEK-293 and
HeLa cells, we tested whether the classical helper virus of
AAV, adenovirus (Ad), could potentiate the transduction of
this mutant (see Fig. S2 in the supplemental material). Ad was
proposed previously to have multiple effects on AAV trans-
duction, from early effects on AAV internalization (3) to the
nuclear delivery of AAV capsids (68), subnuclear effects on the
Mre11-Rad50-Nbs1 DNA repair complex (55), effects that in-
crease the efficiency of second-strand synthesis of AAV ge-
nomes (20, 21), and effects that increase AAV mRNA stability
(52). The coadministration of Ad with rAAV2 and the BR3K
mutant in HEK-293 and HeLa cells dramatically potentiated
transduction (Fig. S2C and S2D). However, Ad did not rescue
the transduction of the BR3K mutant to the level of rAAV2;
it increased the transduction of the mutant and rAAV2 only by
the same order of magnitude. By testing the BR3K mutant
against a battery of Ad mutants, we found that Ad E4 ORF3
and ORF6 are necessary for the Ad-mediated transduction
enhancement of the BR3K mutant (Fig. S2E and S2F). This
finding agrees with what Ferrari et al. reported previously for
rAAV2, which is that the enhancement is through E4 ORF3-
and ORF6-mediated effects on AAV genome processing (20).
Importantly, the observed enhancement that Ad has on the
BR3K mutant indicates that a small number of BR3K
virions are capable of transducing HEK-293 and HeLa cells
despite most capsids being unable to transition to the nucleo-
plasm. Taking this finding into account together with the fact
that measurement of transduction levels in HEK-293 and
HeLa cell lines is not always an accurate predictor of how an
AAV vector will perform in other targets (see Discussion), we
therefore sought to explore whether the restricted transduction
profile of the BR3K mutant was universal in other cells and
tissues.
BR3K transduction efficiency is lower than that of rAAV2
in transformed cells. We began to amass a collection of cell
lines in which the BR3K mutant appeared restricted com-
pared to rAAV2 (HEK-293 cells, HeLa cells, and W162 cells)
(Fig. 8A and data not shown). Surprisingly, we identified sev-
eral cell lines where there were no obvious differences in trans-
duction between the BR3K mutant and rAAV2 (Fig. 8B).
The most striking difference between these groups is that the
former group is transformed (HEK-293 [transformed with the
Ad E1 gene], HeLa [cervical cancer cells associated with hu-
man papillomavirus], and W162 [transformed with the Ad E4
gene] cells) compared to the latter group (HepG2 cells, C2C12
FIG. 6. Fluorescent in situ hybridization depicting that DNA from
the BR3K mutant is delivered to the nucleus during infection. HeLa
cells were infected with rAAV2 or the BR3K mutant (10,000 vg/cell)
for 16 h in the absence (left) or presence (right) of MG132. Cells were
prepped for FISH using an RNA probe complementary to the anti-
sense strand of the TR-Luc genome. No staining in control samples (i
and iv) indicates a lack of nonspecific binding from the probe. Both
rAAV2 (v) and BR3K (vi) genomes (red) are found to accumulate in
the nucleus, specifically in nucleolar regions during proteasome
inhibition.
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cells, and CV1 cells), which are mostly normal cell lines. Al-
though HepG2 cells may appear to be an exception in the
second group, this immortalized line, derived from a hepatic
adenocarcinoma, does not display viral antigens and retains
many characteristics of normal hepatocytes (31).
The availability of CV1 cells and transformed CV1-T cells
allowed us to assess whether effects related to cellular trans-
formation were a primary factor in prohibiting BR3K gene
delivery compared to rAAV2. CV-1 cells were derived from
the kidney of a male African green monkey in 1964 (32) and
transformed to CV1-T cells by the genetic transfer of large T
antigen from SV40 (24). We found that the transduction effi-
ciency of the BR3K mutant was at least 10-fold lower than
that of rAAV2 in CV1-T cells (Fig. 8A). However, in nontrans-
formed CV1 cells, the difference between rAAV2 and BR3K
transduction was found to be less than 2-fold (Fig. 8B). These
results were on a scale similar to what we have seen for other
transformed and nontransformed cell lines (compare Fig. 8A
and B), supporting the hypothesis that the cell-type-specific
restriction of the BR3K mutant is correlated with the trans-
formed status of the target.
The BR3K mutant is able to transduce liver, brain, and
muscle tissue in vivo. To determine if mutant virions per-
formed similarly in nontransformed cells in vivo as they did in
vitro, we administered 1010 vg by tail vein injection to female
BALB/c mice. At 1 week and 2 weeks postinjection, we visu-
alized the bioluminescence of the luciferase reporter in the
liver of these mice (Fig. 8C). Transduction profiles closely
matched those observed for HEK-293 and HeLa cells except
for the BR3K mutant, which produced transgene expression
levels as high as those of rAAV2 (compare Fig. S3A in the
supplemental material to Fig. 1D and E). In addition to exam-
ining BR3K transduction in liver, we also explored whether
this mutant would transduce brain and muscle tissue. We in-
fused rAAV2 or the BR3K mutant into rat striatum by in-
tracerebral injection, and after 2 weeks, coronal sections were
fixed and processed for the immunohistochemical detection of
GFP transgenes (Fig. 8D). No obvious differences were appar-
FIG. 7. HU treatment does not mobilize BR3K capsids to the nucleoplasm. To visualize whether BR3K mutant capsids could be mobilized
into the nucleoplasm in response to HU, we fixed and stained infected HeLa cells for indirect immunofluorescence of capsids (green), nucleolin
(red), and nuclei (blue). Roughly 40 confocal sections that span 5 m were stacked and rendered in three dimensions by using Volocity software
(i). A movie was generated to explore capsid localization in detail by digitally gating first the blue channel (DAPI, representing the nucleus) and
then the red channel (nucleolin, representing the nucleolus), along with increasing the zoom. Images were captured at successive stages in the
movie to reveal the nuclear interior (ii and iii) and the interior of the nucleolus (iv). Both rAAV2 and the BR3K mutant accumulate in the
nucleolus in the presence of proteasome inhibitor (white arrows). Only rAAV2 is localized to nucleoplasmic sites following HU treatment (white
arrowheads, rAAV2; empty arrowheads, BR3K mutant).
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ent between rAAV2 and BR3K transductions in terms of
intensity or cellular targets viewed at higher magnifications
(Fig. 8E). We have also compared rAAV2 and BR3K trans-
ductions following intramuscular injections into the hind limb
of female BALB/c mice, and again, the transduction patterns
of the two vectors were indistinguishable in vivo (Fig. 8F and
Fig. S3B). Furthermore, the nonrestricted transduction pattern
of the BR3K mutant in vivo in liver and muscle tissue closely
matched what was observed for cultured cell lines in vitro for
HepG2 cells (human liver cells) and C2C12 cells (mouse myo-
blasts). These results demonstrate that the transduction of the
BR3K mutant is not species specific and that BR3K infec-
tion is not restricted compared to that of rAAV2 in normal
cells and tissues, in contrast to transformed cells, emphasizing
the importance of testing AAV-based vector transduction with
a variety of targets.
DISCUSSION
Several adeno-associated virus (AAV) serotypes are emerg-
ing as popular tools for gene therapy. While research efforts on
the AAV capsid have focused largely on how residues can be
manipulated to avoid neutralizing antibodies or direct target-
ing to specific tissues, how capsid residues modulate subcellu-
lar trafficking and influence transduction is less understood.
Research on subcellular events in AAV infection has garnered
increasing interest, as several groups are now demonstrating
that the nuclear delivery of the genome is a major barrier to
transduction (16, 18, 28, 56, 68, 72). To more clearly under-
stand the trafficking profile of the prototypical serotype,
AAV2, and to explore how virion components modulate sub-
cellular trafficking, we have studied a panel of capsid mutants
with deletions or substitutions in the unique N-terminal re-
FIG. 8. The BR3K mutant is significantly less efficient than rAAV2 in transformed cells but is indistinguishable from rAAV2 in liver, brain,
and muscle tissue in vivo. (A) Transformed cell lines such as HEK-293, HeLa, or CV1-T cells were inoculated with rAAV2 or the BR3K mutant
(1,000 vg/cell) (TR-CBA-Luc transgene) and assayed for transduction efficiency after 24 h. rAAV2 transduction was at least 10-fold-more efficient
than that of the BR3K mutant in these cell lines. (B) The normal cell lines HepG2 (human liver cells), C2C12 (mouse myoblasts), and CV1
(green monkey kidney cells) were assayed for transduction efficiency of rAAV2 or the BR3K mutant under the same conditions as those
described above (A). The transduction efficiencies of rAAV2 and the BR3K mutant in nontransformed cells were similar (within 2-fold) (*, P
value of 0.01 for A and B). Note that HepG2 cells are derived from an adenocarcinoma but contain no viral antigens and display many
characteristics of normal hepatocytes. (C) rAAV2 or mutant virions (1010 vg) were administered by tail vein injection to female BALB/c mice, and
bioluminescent luciferase activity was visualized 1 and 2 weeks later. The color scale bar represents photons/s/cm2, and data shown are
representative images of a single mouse from three to four mice per vector group. (D) rAAV2 or BR3K packaging GFP transgenes (3.8  108
vg) was infused into rat striatum by intracerebral injection. Two weeks postinjection, brains were fixed and coronal sections were processed to
detect GFP using DAB as a substrate and nickel-cobalt intensification. (E) Higher magnification of images from coronal sections similar to those
in D depicting the transduction of neurons and associated processes (dark staining). (F) Bioluminescence images of transduction following
intramuscular injections of rAAV2 (right hind limb) and BR3K (left hind limb) packaging Luc transgenes acquired 2 weeks postinjection.
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gions of the capsid proteins VP1 and VP2 (Fig. 1). Here we
report that these mutants are able to assemble into capsids,
package DNA similarly to the wild type, internalize into cells,
and traffic through a perinuclear region in the vicinity of the
Golgi apparatus. These mutants could be grouped into two
classes: class I mutants (BR1, BR2, and BR2K), which
were partially deficient, and class II mutants (VP3only, 75HD/
AN, BR3, and BR3K), which were markedly deficient. Mu-
tations that introduced neutral residues into the positively
charged NLS-like regions (BR2 and BR3) yielded capsids
that had a more diffuse localization pattern consistent with a
loss of NLS activity. One particularly striking class II mutant,
BR3K, was found to carry its genome to the nucleus but was
10- to 100-fold-less infectious than rAAV2 in transformed cell
lines such as HEK-293, HeLa, W162, and CV1-T cells. We
speculate that additional positive charges in VP1 or VP2 may
restrict the nuclear mobilization or uncoating of capsids and
limit transduction in a transformed-cell-specific fashion.
For several years now, the subcellular trafficking of AAV
upstream of nuclear entry has been studied. Although the
details are not yet in focus, a general route of trafficking has
been established, from virus binding, to endocytosis, to perinu-
clear accumulation, which depends on the activation of Rac1
and phosphatidylinositol 3-kinase (53). In our studies, a signif-
icant fraction of mutant capsids appear to traffic through the
Golgi apparatus (Fig. 2), as was previously shown for AAV2
and AAV5 (2, 47). It is interesting that classical retrograde
trafficking from the Golgi apparatus depends on COPI inter-
actions with cytoplasmically exposed dilysine (KKXX) se-
quences on target proteins (9, 38). Transmembrane proteins
that present this sequence to the cytoplasm are recognized by
components of the coatomer protein complex, which then send
these targets in vesicles from the Golgi apparatus toward the
endoplasmic reticulum (ER). It seems plausible that the cell
could process rAAV2 capsids through this sorting pathway,
since two dilysine sequences are found in the N terminus
of VP1, and mutating one of them (BR1 [120QAKKR/
QANNR]) appears to increase localization in Golgi-associ-
ated regions (Fig. 2 and 4).
It is important to consider that the cellular environment
could play a role in regulating the function of VP1. Specifically,
concerning the viral phospholipase domain in VP1, it should
be mentioned that Golgi membranes are known to be a pri-
mary target for endogenous cytosolic PLA2 activity (22). Our
observation that Golgi-associated capsids display exposed VP1
N termini (Fig. 3 and data not shown) could be interpreted as
the virus attempting to target an area where the chance of
PLA2-mediated membrane disruption is high. The propensity
of cellular PLA2 to cleave phospholipids into arachadonic acid
is typically regulated by both intracellular Ca2 levels and the
phosphorylation of residues near the catalytic domain of PLA2.
Not surprisingly, the N terminus of VP1 contains several po-
tential phosphorylation sites and a GXG calcium-binding site.
Structural modeling of VP1 predicts that the N terminus can
translocate through the 5-fold axis of symmetry in the capsid
and permit the exposure of the first 185 residues in VP1 (36).
Since it requires only 18 to 20 amino acids to span a phospho-
lipid bilayer, this would be of sufficient length to allow the
presentation of the NLS regions and dilysine sequences to the
cytosol if the PLA2 domain had penetrated through a Golgi or
endosomal membrane. Perhaps future work will uncover
whether the PLA2 domain in AAV operates optimally in a
specific vesicular compartment, prefers a specific phospholipid
substrate, or functions at multiple cellular membranes such as
the endosome and the nuclear envelope or if its activity is
regulated by components of the cellular environment.
Clearly, infection by AAV and other parvoviruses requires
positive charges near the N terminus of VP1 (27, 41, 56, 61)
that putatively direct nuclear targeting. As stated above, the
nuclear accumulation of AAV virions is potentiated through
an unknown mechanism when the ubiquitin/proteasome sys-
tem is compromised. Rather strikingly, proteasome inhibitors
drove the accumulation of BR3K mutant virions into the
nucleolus, as we have previously described for rAAV2 (33), but
did not increase the transduction of this mutant (Fig. 4 and 6).
This result yielded a clear separation of proteasome inhibitor-
mediated effects on the capsid from effects on gene expression
and suggested that BR3K transduction is blocked at a point
after nuclear entry. Apparently, a few BR3K genomes are
able to serve as templates for transgene expression, since trans-
duction is enhanced by Ad E4 genes (see Fig. S2 in the sup-
plemental material), which increase the efficiency of genome
or mRNA processing and are not thought to affect the AAV
capsid. Taken together, our results provide evidence that the
primary mechanism by which proteasome inhibitors increase
AAV transduction occurs upstream of nucleoplasmic mobili-
zation or uncoating. We attempted to see if proteasome inhib-
itor-mediated effects on the capsid could be combined with
Ad-mediated effects on the genome to rescue BR3K trans-
duction, but cooperation or synergy could not be obtained
(data not shown), most likely due Ad E4 ORF3 and ORF6
requiring active proteasomes to enhance viral gene expression
(8). Nonetheless, a major conclusion from our experiments
demonstrating that the BR3K mutant enters the nucleus in
HeLa cells (without being infectious) is that nuclear entry is
not sufficient for the transduction of AAV, at least in trans-
formed cells.
Our knowledge of how cellular parameters govern AAV
transduction is still in its infancy, and many serotypes behave
differently in vitro compared to in vivo. AAV8 is a prototypical
example; it is heralded as one of the better capsids for target-
ing mouse liver in vivo and is capable of transducing 100% of
mouse hepatocytes after injection through the portal or tail
vein (45). In contrast, AAV8 does not efficiently transduce
cells in tissue culture. This pattern is somewhat similar to what
we have observed for the BR3K mutant, where it was unable
to efficiently transduce several transformed cell lines in vitro
(Fig. 1 and 8) but was indistinguishable from rAAV2 in un-
transformed cell lines and tissues in vivo (Fig. 8 and 9). Cellular
transformation from small DNA tumor viruses, such as Ad,
SV40, and papillomavirus, centers on the inactivation of the
tumor suppressor p53 (39). Studies of the large T antigen from
SV40 have shed light on the multitude of pathways that are
affected in transformed cells, including molecular interactions
that interfere with the heat shock chaperone hsc70, the reti-
noblastoma family (Rb family) of tumor suppressors, and p53
(1). Future work may uncover how the perturbation of these
factors may specifically influence and restrict BR3K trans-
duction.
Although no consensus sequence has been identified for
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nucleolar targeting, proteins that are trafficked to the nucleolus
contain sequences that resemble NLS motifs (19). It is possible
that the additional lysine residue in BR3 could essentially
“target and trap” the virus in the nucleolus, preventing it from
uncoating in the nucleoplasm (Fig. 9). If the lysine substitution
in the BR3K mutant generates a stronger nucleolar localiza-
tion signal, this may explain why the BR3K mutant is less
infectious than rAAV2 in transformed cells, given that high
levels of nucleolar proteins are found in tumor cells (57) to the
degree that in certain cases, levels of nucleolar proteins are
used as a diagnostic marker for cancer. We know from our
previous studies that infectious virions can accumulate in the
nucleolus (33). Treatments that disrupt the nucleolus (such as
HU or small interfering RNA [siRNA]-mediated knockdown
of nucleolar proteins) result in the mobilization of capsids into
the nucleoplasm and correlate with increases in transduction.
The BR3K mutant might be terminally targeted to the nu-
cleolus in transformed cells and unable to escape to an envi-
ronment favorable for uncoating. In contrast, rAAV2 might
contain weaker nucleolar localization properties, which could
function to target capsids to the stable environment of the
nucleolus during assembly (65) or infectious entry (33), yet be
flexible enough to transition to the nucleoplasm if favorable
conditions arose in the cell that were permissive for infection.
With future work it will be interesting to determine if other
serotypes besides AAV2 employ this subcellular strategy of
maneuvering to nucleolar reservoirs or mobilizing to the nu-
cleoplasm, since a high degree of sequence conservation is
found in the NLS-like regions of VP1 and VP2. Ultimately, the
BR3K mutant and other vectors that we have generated in
this study should prove valuable as we continue to dissect the
trafficking and transduction profiles of AAV variants with new
molecular tools.
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